By Cassandra Galloway, Director, Client Partnerships, On-Demand Talent Solutions
A Fortune 500 organization came to us with a clear-eyed view of what was ahead. They had an aggressive acquisition strategy, and leadership knew that M&A activity was going to become a primary growth lever over the next several years. Rather than waiting for deals to close and reacting in the moment, they asked a better question early: how do we build the infrastructure now so we are not reinventing the wheel every time?
We partnered with them to stand up an Integration Management Office and develop a repeatable playbook for future acquisitions. Instead of each deal becoming a fire drill, they created operational consistency that reduced disruption, accelerated integration timelines, and kept internal leaders focused on their actual work. The ROI compounded with every subsequent acquisition.
What made it work was not a larger budget or a bigger team. It was the timing – the decision to prepare before the need became urgent. They saw the inflection point coming and chose to meet it with intention rather than scramble through it.
Where the Gaps Tend to Surface
In life sciences, the question is not whether a company will face an inflection point. It is whether they will see it coming in time to act. These moments, from regulatory submissions to commercial launch to M&A integration, often signal a shift in what the organization needs to be successful. The people, processes, and expertise that supported one phase of growth may need to evolve to support the next.
Certain functions are chronically under-resourced at specific stages. In earlier-stage biotech, regulatory, quality, and CMC are often underbuilt because leadership is appropriately focused on science and clinical progress. In MedTech, manufacturing engineering, quality systems, and design controls tend to stretch thin as companies move toward commercialization. During M&A activity, PMO leadership, change management, and quality harmonization are frequently under-resourced because organizations assume existing leaders can absorb integration work alongside their day jobs. Commercial launch readiness follows the same pattern: companies that have spent years focused on trial milestones often find themselves closer to launch than they expected, suddenly needing infrastructure they have not yet built. In each case, the challenge is not a lack of talent. It is a mismatch between the demands of the next business milestone and the resources currently in place to support it.
The Real Cost of Waiting
The obvious costs of reactive hiring include delays, missed milestones, and searches conducted under pressure. But the less visible costs tend to be the most damaging. When reactive mode sets in, senior leaders who should be focused on strategy find themselves managing tactical problems instead. In life sciences, a six-month delay can translate to millions in lost opportunity, investor pressure, or competitive disadvantage.
What surprises even experienced leadership teams is how quickly the situation compounds. A quality or compliance issue that might have been contained with earlier intervention can consume months of leadership attention and require far more resources than proactive planning ever would have. The companies that recognize strain early, before it becomes a crisis, are the ones positioned to respond rather than recover.
The Conversation That Changes Everything
The most effective talent conversations I have with clients start with one question: what business milestone are we trying to reach, and what expertise will that require that you do not currently have? From there, we work backwards. What does success look like? What could derail it? What can internal teams realistically absorb?
The companies that are ready to have that conversation share one quality: self-awareness. The strongest leadership teams are honest about what they do well and where they need help. They do not view outside expertise as a concession. They view it as acceleration.
Choosing the Right Engagement Model
One of the most practical questions I work through with clients is whether a situation calls for a full-time hire, a time bound resource, or both. Three questions usually clarify it:
• Is this a long-term capability or a milestone-specific need? Work tied to a defined initiative, whether remediation, tech transfer, integration, or launch preparation, often calls for consulting expertise rather than a permanent hire.
• How urgent is the need? A consultant can often be activated in days or weeks, while a permanent hire may take months to identify, onboard, and become fully effective. Bringing in expertise immediately can prevent a capability gap from becoming a timeline risk.
• Is the organization clear on what it actually needs? Sometimes companies know they have a problem but have not yet defined the solution or profile required. Bringing in an experienced operator to stabilize and build the roadmap before committing to a permanent hire is often the smartest first move.
The organizations that navigate inflection points best are not necessarily the ones with the largest teams or biggest budgets. They are the ones that recognize change early and activate the right expertise before execution risk appears. In life sciences, timing matters just as much as talent and the cost of waiting is often far greater than the cost of preparation.
